The demographics of aging suggest a great need for the early diagnosis of dementia and
the development of preventive strategies. Neuropathology and structural MRI studies have …

Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder associated with
progressive loss of cognitive function. 2-[18 F] fluoro-2-deoxy-d-glucose (FDG) positron …

The early diagnostic value of glucose hypometabolism and atrophy as potential
neuroimaging biomarkers of mild cognitive impairment (MCI) and Alzheimer's disease (AD) …

Positron emission tomography (PET) with 18 F-2-fluoro-2-deoxy-D-glucose (FDG)
demonstrates a typical pattern of impairment of regional metabolic rates of glucose …

While significantly reduced glucose metabolism in fronto-temporo-parietal and cingulate
cortices has been demonstrated in Alzheimer's disease (AD) compared with controls …

Assessment of regional cerebral glucose metabolism by 18F-2-fluoro-2-deoxy-d-glucose
(FDG)-PET at resting state is a standard functional technique to assess cerebral function …

The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit
from biomarkers that are sensitive to the subtle brain changes that occur in the preclinical …

Purpose The purpose of the study was the identification of group and individual subject
patterns of cerebral glucose metabolism (CMRGlu) in patients with Alzheimer's disease (AD) …

Measurement of local cerebral glucose metabolism (lCMRGlc) by positron emission
tomography (PET) and 18 F-2-fluoro-2-deoxy-d-glucose (FDG) has become a standard …

Background Subjects with amnesic mild cognitive impairment (aMCI) may include patients at
high risk for progression to Alzheimer disease (AD) and a population with different …